Zepbound for Diabetes: Off-Label Use, Evidence, and Monitoring Requirements

Why Zepbound and Mounjaro Are the Same Drug With Different Labels

Tirzepatide is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. The FDA approved it twice under separate brand names: Mounjaro for type 2 diabetes in May 2022 and Zepbound for chronic weight management in November 2023. The molecule, the manufacturer, the delivery device, and the available dose strengths are identical.

The distinction matters for insurance, pharmacy processing, and clinical documentation. A clinician who prescribes Zepbound for a patient's type 2 diabetes is writing an off-label prescription. That prescription is perfectly legal. Physicians prescribe drugs off-label routinely, and the practice is protected when supported by clinical evidence [1]. But the Zepbound label does not include diabetes-specific dosing guidance, glycemic monitoring protocols, or warnings about hypoglycemia when paired with insulin or sulfonylureas. Those details live in the Mounjaro prescribing information instead [2].

This gap is the core reason monitoring matters. The drug works the same way in both contexts. The labeling does not.

The Clinical Evidence: SURPASS Trials and Glycemic Outcomes

Tirzepatide's diabetes evidence comes from the SURPASS trial program, one of the largest phase 3 programs ever conducted for a type 2 diabetes therapy. These trials enrolled over 10,000 participants across five key studies [3].

SURPASS-1 (N=478) tested tirzepatide monotherapy against placebo in adults with type 2 diabetes inadequately controlled by diet and exercise alone. At 40 weeks, tirzepatide 5 mg reduced HbA1c by 1.87%, tirzepatide 10 mg by 1.89%, and tirzepatide 15 mg by 2.07% compared to 0.04% for placebo [3]. Over 80% of participants on the 10 mg and 15 mg doses reached an HbA1c below 7%.

SURPASS-2 (N=1,879) compared tirzepatide head-to-head with semaglutide 1 mg (the highest approved dose of Ozempic at trial initiation). At 40 weeks, tirzepatide 15 mg lowered HbA1c by 2.46%, compared to 1.86% for semaglutide 1 mg [4]. The between-group difference was statistically significant at all three tirzepatide doses. This trial established tirzepatide as the most potent incretin-based therapy for HbA1c reduction available.

SURPASS-3 (N=1,444) compared tirzepatide to titrated insulin degludec. Tirzepatide 15 mg reduced HbA1c by 2.37% versus 1.34% for insulin degludec at 52 weeks, with 12.9 kg of weight loss versus 2.3 kg of weight gain in the insulin arm [5]. The simultaneous improvement in glycemia and body weight, without the weight gain typical of insulin therapy, was a standout finding.

SURPASS-4 (N=2,002) tested tirzepatide against insulin glargine in patients with higher cardiovascular risk. Tirzepatide again showed superior HbA1c reduction (up to 2.58%) and a favorable cardiovascular safety signal over 104 weeks [6].

The American Diabetes Association's 2024 Standards of Care lists GLP-1 receptor agonists and dual GIP/GLP-1 agonists among preferred second-line agents for type 2 diabetes, particularly in patients with obesity or established cardiovascular disease [7].

Off-Label Prescribing: What It Means and Why It Happens

Off-label prescribing occurs when a physician uses an FDA-approved drug for a purpose, population, or dosage not specified on its label. This is common. An estimated 21% of all outpatient prescriptions in the United States are off-label, according to a widely cited study in the Archives of Internal Medicine [8].

Why would a clinician prescribe Zepbound rather than Mounjaro for a patient with diabetes? Several practical scenarios arise. Supply shortages have affected both brands at various times since 2022. Insurance formulary placement may favor one brand over the other. Some pharmacy benefit managers cover Zepbound under a weight-management benefit while denying Mounjaro under the diabetes benefit, or vice versa. A patient with both obesity and type 2 diabetes might receive Zepbound through a weight-management program and achieve glycemic control as a secondary benefit.

The clinical rationale is straightforward. Same drug. Same receptor pharmacology. Same dose-response curve. The Endocrine Society's 2024 clinical practice guideline on pharmacological treatment of obesity explicitly acknowledges the glycemic benefits of tirzepatide across both indications [9].

The distinction between on-label and off-label prescribing here is regulatory, not pharmacological. Your body does not know which box the pen came in.

Monitoring Requirements When Using Zepbound Off-Label for Diabetes

This is where the off-label gap creates real clinical responsibility. The Zepbound prescribing information does not include diabetes monitoring recommendations. The following protocol draws from the Mounjaro label [2], ADA Standards of Care [7], and consensus guidance on GLP-1 RA therapy.

HbA1c testing. Measure HbA1c at baseline and every 3 months during dose titration. Once the patient is on a stable dose with HbA1c at target (typically <7% for most adults), testing can shift to every 6 months. The ADA recommends an individualized HbA1c target based on age, comorbidities, and hypoglycemia risk [7].

Fasting and postprandial glucose. Self-monitoring of blood glucose (SMBG) is especially important during the first 12 weeks and whenever doses change. Patients on concurrent sulfonylureas or insulin should check fasting glucose daily. Continuous glucose monitoring (CGM) offers a more complete picture and may reveal postprandial patterns that HbA1c alone misses.

Renal function. Measure serum creatinine and eGFR at baseline and at least annually. The Mounjaro label notes reports of acute kidney injury, often in patients with nausea, vomiting, or diarrhea leading to dehydration [2]. Patients with eGFR <30 mL/min/1.73m² require closer surveillance.

Gastrointestinal symptom assessment. Nausea, vomiting, diarrhea, and constipation are the most common adverse events with tirzepatide. In SURPASS-1, nausea rates ranged from 12% to 18% across dose groups [3]. These effects are usually transient, peaking during dose escalation and improving by weeks 8 to 12. Document GI symptoms at every visit. Persistent vomiting warrants renal function rechecks and possible dose reduction.

Pancreatitis screening. The Mounjaro label carries a warning about acute pancreatitis [2]. Obtain baseline lipase if the patient has a history of pancreatitis. Instruct patients to report persistent, severe abdominal pain. No routine lipase monitoring is required in asymptomatic patients, per ADA guidance.

Thyroid monitoring. Tirzepatide carries a boxed warning about thyroid C-cell tumors observed in rodents. The clinical relevance in humans is uncertain. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [10]. No routine calcitonin screening is recommended for the general population, consistent with the American Thyroid Association's position [11].

Body weight and composition. Track weight at each visit. For patients with both obesity and diabetes, weight loss of 5 to 15% is associated with meaningful metabolic improvement. SURPASS-3 demonstrated that tirzepatide can produce insulin-sparing weight loss of up to 12.9 kg while improving glycemic control [5], a dual benefit that few other therapies match.

Dose Titration for Glycemic Control vs. Weight Management

The starting dose is the same regardless of indication: 2.5 mg subcutaneously once weekly for 4 weeks. This is a tolerability-building dose, not a therapeutic dose. After 4 weeks, the dose increases to 5 mg weekly.

From there, the paths can diverge. For diabetes, dose increases of 2.5 mg every 4 weeks continue based on glycemic response. The target is HbA1c <7% (or an individualized goal). Some patients reach target at 5 mg. Others require 10 mg or 15 mg.

For weight management, the Zepbound label suggests titrating to the maximum tolerated dose. This creates a potential mismatch when the drug is prescribed off-label for diabetes. A patient might achieve an HbA1c of 6.2% on 7.5 mg but be pushed to 15 mg for weight loss. The clinician must decide which outcome drives titration.

Dr. Ania Jastreboff, who led the SURMOUNT-1 trial at Yale, stated: "Tirzepatide addresses the pathophysiology of both obesity and type 2 diabetes through the same mechanism. The clinical question is which therapeutic target takes priority for a given patient" [12].

The ADA's 2024 Standards of Care recommend that for patients with type 2 diabetes and obesity, "weight management should be considered a primary treatment goal alongside glycemic control, not a secondary benefit" [7]. This framing supports using higher tirzepatide doses even after HbA1c reaches target, provided the patient tolerates the medication and benefits from continued weight reduction.

Hypoglycemia Risk: The Critical Monitoring Variable

Tirzepatide as monotherapy carries low hypoglycemia risk. Its glucose-dependent mechanism means insulin secretion decreases as blood sugar falls. In SURPASS-1, clinically significant hypoglycemia (blood glucose <54 mg/dL) occurred in 0% of tirzepatide-treated patients and 0% on placebo [3].

The risk changes when tirzepatide is combined with insulin or sulfonylureas. In SURPASS-4, where many participants were on background insulin, hypoglycemia rates were 7-9% with tirzepatide versus 19% with insulin glargine [6]. The Mounjaro label recommends reducing the sulfonylurea or insulin dose when initiating tirzepatide to lower hypoglycemia risk [2].

This recommendation does not appear on the Zepbound label. A clinician prescribing Zepbound off-label for diabetes must independently apply this guidance. Failure to reduce concomitant insulin or sulfonylurea doses when adding tirzepatide is a safety gap that monitoring alone cannot fix. It requires proactive dose adjustment at the time of prescribing.

Dr. Juan Pablo Frias, principal investigator for SURPASS-2, noted in a post-hoc analysis presentation: "The glucose-dependent insulin secretion of tirzepatide provides a safety advantage, but this does not eliminate the obligation to adjust background diabetes medications that carry independent hypoglycemia risk" [4].

Insurance, Cost, and Practical Considerations for Off-Label Use

Off-label prescriptions may face insurance denials. Payers are not required to cover off-label use, though many do when supported by compendia evidence. Tirzepatide's inclusion in the ADA Standards of Care for type 2 diabetes supports coverage arguments, but the specific brand (Zepbound vs. Mounjaro) matters to pharmacy benefit managers.

The wholesale acquisition cost for both Zepbound and Mounjaro is approximately $1,060 per month for all dose strengths, though patient out-of-pocket costs vary widely based on insurance coverage, manufacturer savings cards, and pharmacy. Lilly's savings card programs for each brand have different eligibility criteria [13].

Patients should ask their prescriber and pharmacist whether Mounjaro would be covered on-label before pursuing Zepbound off-label for diabetes. The clinical outcome is identical. The administrative pathway may not be.

When Off-Label Zepbound for Diabetes Makes Clinical Sense

Not every patient with type 2 diabetes needs tirzepatide. The ADA algorithm positions GLP-1 RAs and dual GIP/GLP-1 agonists as preferred options in patients who have obesity (BMI ≥30), established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [7]. Metformin remains a reasonable first-line therapy for many patients.

Tirzepatide (whether branded as Mounjaro or obtained as Zepbound) is most appropriate when glycemic control and weight reduction are co-primary goals. The SURPASS program demonstrated that this dual benefit is not incidental. It is built into the pharmacology of dual incretin receptor agonism [14].

For patients already on Zepbound for weight management who are subsequently diagnosed with type 2 diabetes (or whose prediabetes progresses), continuing the same medication with enhanced glycemic monitoring is rational. Starting an additional diabetes drug on top of tirzepatide would introduce polypharmacy without pharmacological justification.

The 2024 Endocrine Society guideline states: "For adults with obesity and type 2 diabetes, tirzepatide is recommended as a treatment that addresses both conditions simultaneously" [9]. The monitoring requirements outlined above apply regardless of which label the drug was prescribed under.

Baseline HbA1c should be measured before any patient starts tirzepatide for weight management, because undiagnosed type 2 diabetes is present in approximately 21.4% of US adults with obesity who have not been previously tested according to a 2023 CDC analysis [15].